# PE0116 Injection in Treatment of Patients With Advanced Solid Tumours

> **NCT05800249** · PHASE1 · COMPLETED · sponsor: **Shanghai HyaMab Biotech Co.,Ltd.** · enrollment: 31 (actual)

## Conditions studied

- Locally Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** PE0116

## Key facts

- **NCT ID:** NCT05800249
- **Lead sponsor:** Shanghai HyaMab Biotech Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-08
- **Primary completion:** 2023-06-02
- **Final completion:** 2023-06-16
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05800249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05800249, "PE0116 Injection in Treatment of Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05800249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*